5 Stocks Boosting The Drugs Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 79 points (0.5%) at 15,295 as of Wednesday, May 15, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,703 issues advancing vs. 1,237 declining with 128 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.6%. Top gainers within the industry include Eli Lilly and Company ( LLY), up 2.0%, Abbott Laboratories ( ABT), up 1.6%, GlaxoSmithKline ( GSK), up 1.5%, Novartis ( NVS), up 1.4% and AstraZeneca ( AZN), up 0.8%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Bristol-Myers Squibb Company ( BMY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Bristol-Myers Squibb Company is up $3.02 (7.15) to $45.23 on heavy volume Thus far, 17.7 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.1 million shares. The stock has ranged in price between $42.16-$45.36 after having opened the day at $42.22 as compared to the previous trading day's close of $42.21.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $67.2 billion and is part of the health care sector. The company has a P/E ratio of 46.0, above the S&P 500 P/E ratio of 17.7. Shares are up 29.5% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 13 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact